Revvity stock holds steady as Q1 2026 growth and margin expansion underpin valuation
Published on 07/21/2026 at 07:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Revvity Inc. (US76155R1086) stock is underpinned by the companys latest quarterly update, where management reported low single digit revenue growth and improved adjusted operating margins for Q1 2026 as part of its ongoing transformation following the separation from PerkinElmers applied, food and enterprise services units in 2022.
Q1 2026 revenue grows in low single digits
According to the companys most recent quarterly communication in 2026, Revvity generated approximately mid single digit percentage year on year revenue growth in Q1 2026, building on its 2025 base as it focused on life sciences and diagnostics solutions.
Management indicated that organic revenue growth in Q1 2026 was positive compared with Q1 2025, supported by demand in diagnostics and life science research tools, even as some industrial and applied markets that were divested in the 2022 transaction no longer contributed to reported sales.
Margin expansion and guidance reiteration
In the same Q1 2026 update, Revvity reported that its adjusted operating margin expanded by several tens of basis points compared with the prior year period, reflecting cost actions, portfolio focus on higher margin diagnostics and life sciences, and synergies from the post spin cost structure.
The company reiterated its full year 2026 guidance framework, signaling expectations for continued low to mid single digit revenue growth and further gradual margin expansion compared with 2025, supported by cost initiatives and mix benefits toward higher value diagnostics and life sciences offerings.
More on Revvity fundamentals and valuation
Further details on Revvity stock, including historic financials, segment performance and upcoming events, can be found in additional coverage and the companys filings.
Genomic and diagnostics platforms support growth
A central pillar of Revvitys strategy is its portfolio of life sciences and diagnostics platforms, which generate the majority of revenue after the spin off of lower growth applied and food testing businesses that closed in 2022.
The company provides instruments, reagents and software for genomics, cellular analysis and imaging, as well as diagnostic solutions for reproductive health, infectious diseases and other conditions, creating a mix that tends to support recurring revenue from consumables and services.
Revvity stock and market position
Revvity stock represents a pure play exposure to life sciences and diagnostics markets after the companys rebranding and portfolio reshaping, with investors monitoring revenue trends, margin improvements and capital allocation as the transformation continues.
The shares are typically traded on a major US exchange in US dollars, and the companys market capitalization reflects investor expectations for sustainable mid single digit revenue growth and further efficiency gains in the coming years.
Revvity Inc. key data
- Company: Revvity Inc.
- ISIN: US76155R1086
- Ticker: NYSE: RVTY
- Trading venue: NYSE
- Sector / Industry: Health Care / Life Sciences Tools and Services
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
